Where is iniuva located?

iniuva is headquartered in Hamburg, Germany.

Is iniuva a funded company?

iniuva is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does iniuva rank among its competitors?

iniuva ranks 118th amongst 162 active competitors, of which 67 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was NewLimit, which secured $435M in Jun, 2026.

Who are the top competitors of iniuva?

iniuva's top competitors include Evotec, DNAnexus and Insitro. Among them, NewLimit secured the most recent funding round in June, 2026.

iniuva - 2026 Company Profile, Team & Competitors

iniuva is an unfunded company based in Hamburg (Germany), founded in 2019. It operates as an AI-powered company that focuses on orphan drug development. iniuva has not raised any funding yet. The company has 162 active competitors, including 67 funded and 9 that have exited. Its top competitors include companies like Evotec, DNAnexus and Insitro.

Company Details

AI-powered company that focuses on orphan drug development. It uses AI technology to restore the form and function of proteins addressing protein misfolding in various genetic diseases.

Website: iniuva.com
Email ID: *****@iniuva.com
Phone Number: +49 **********

Key Metrics

Founded Year

2019

Location

Hamburg, Germany

Stage

Unfunded

Ranked

118^th among 162 active competitors

Similar Companies

Evotec & 186 more

View iniuva's full profile

iniuva has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of iniuva include Evotec, DNAnexus and Insitro. Here is the list of Top 10 competitors of iniuva, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Evotec 1993, Hamburg (Germany), Public	AI-driven life science company accelerating drug discovery and development	$25.1M	Gilde Healthcare, Eiffel Investment Group ... & 22 others	76/100
2nd	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	71/100
3rd	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
4th	Immunai Technologies 2018, United States, Series B	Developer of next-generation of immunomodulatory therapeutics	$295M	TLV Partners, Viola Group & 14 others	66/100
5th	Asimov 2017, Boston (United States), Series B	Provider of integrated suite for advanced genetic design and manufacturing	$234M	Andreessen Horowitz, Horizons Ventures & 11 others	65/100
6th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, Farallon Capital Management ... & 22 others	64/100
7th	Kinomica 2017, Macclesfield (United Kingdom), Series A	Provider of a bioinformatics platform for the development of precision medicine	$5.16M	BGF, Longwall Venture Partners & 15 others	64/100
8th	Relation 2019, London (United Kingdom), Seed	AI-based drug development tools for researchers	$116M	DCVC, Magnetic Ventures & 9 others	64/100
9th	NewLimit 2022, San Francisco (United States), Series C	Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension	$682M	Founders Fund, Lilly & 21 others	63/100
10th	Somite 2023, Boston (United States), Series A	AI-driven platform to produce human tissue for cell-based therapies	$60M	Khosla Ventures, Astellas Venture Management ... & 13 others	63/100
118th	iniuva 2019, Hamburg (Germany), Unfunded	AI-powered company that focuses on orphan drug development	-	-	24/100